Skip to main content
. 2022 Oct 23;13(23):3384–3392. doi: 10.1111/1759-7714.14697

TABLE 3.

Treatment‐related AEs

Induction phase Maintenance phase
Any AE 35/40 (87.5) 9/25 (36.0)
Gr I–II 22 (53.7) 6 (24.0)
Gr III–IV 26 (63.4) 4 (16.0)
Grade I–II Grade III–IV Grade I–II Grade III–IV
Neutropenia 7 (17.5) 18 (45.0)
Neutropenic fever 0 (0.0) 5 (12.5)
Anemia 7 (17.5) 4 (10.0)
Thrombocytopenia 9 (22.5) 1 (2.5)
Acute kidney injury 4 (10.0) 1 (2.5)
Nausea 0 (0.0) 3 (7.5)
Diarrhea 2 (5.0) 0 (0.0)
Liver function abnormality 2 (5.0) 1 (2.5)
Hiccup 1 (2.5) 0 (0.0)
Anaphylaxis 0 (0.0) 1 (2.5)
Pneumonia 1 (2.5) 1 (2.5)
Hypotension 1 (2.5) 0 (0.0)
Oral thrush 1 (2.5) 0 (0.0)
Polyneuropathy 0 (0.0) 1 (2.5)
Immune‐related AEs
Hyperthyroidism 1 (4.0) 0 (0.0)
Hypothyroidism 1 (4.0) 0 (0.0)
Pancreatitis 0 (0.0) 1 (4.0)
Hepatitis 0 (0.0) 1 (4.0)
Pneumonitis 0 (0.0) 1 (4.0)
Colitis 1 (4.0) 0 (0.0)
Adrenal insufficiency 1 (4.0) 0 (0.0)
AKI 1 (4.0) 1 (4.0)
Thrombocytopenia 1 (4.0) 0 (0.0)

Abbreviations: AE, adverse events; AKI, acute kidney injury; Gr, grade.